COMPARATIVE SAFETY STUDY OF TWO COMMERCIALISED VACCINES AGAINST CANINE BABESIOSIS INDUCED BY BABESIA CANIS

COMPARATIVE SAFETY STUDY OF TWO COMMERCIALISED VACCINES AGAINST CANINE BABESIOSIS INDUCED BY BABESIA CANIS The safety of two vaccines available on the French market against canine babesiosis - Nobivac Piro (R) (NP) and Pirodog (R) - (P) have been evaluated. Their local, general and biochemical impacts have been compared in a controlled experimental study. Three groups were used: a control group (T) and two groups vaccinated twice at 21 days interval. All dogs presented moderate local reaction. However, either clinical and biological parameters showed that the NP group presented a significantly more intense reaction at the injection site compared to the P group. No statistical difference has been revealed between the groups P and T evolutions.